The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.70
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (0.398%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 50.70
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

15 Jun 2023 13:19

RNS Number : 8821C
IP Group PLC
15 June 2023
 

FOR RELEASE ON

15 June 2023

 

IP Group plc - Results of Annual General Meeting

 

The Annual General Meeting ("AGM") of IP Group plc was held earlier today. All of the Resolutions proposed at the AGM were passed by the appropriate majority on a poll.

 

IP Group plc Annual General Meeting Poll Results

 

 

RESOLUTION

VOTESFOR

%

VOTESAGAINST

%

VOTESTOTAL

% of ISC VOTED

VOTESWITHHELD

1

To receive the Directors' Report, the Audited Statement of Accounts and Auditor's Report of the Company for the financial year ended 31 December 2022.

751,809,999

99.99

23,443

0.01

751,833,442

72.51

5,668,073

2

To approve the Directors' Remuneration Report for the year ended 31 December 2022.

643,188,184

85.99

104,756,327

14.01

747,944,511

72.13

9,557,004

3

To declare the final dividend for the year ended 31 December 2022.

757,477,036

99.99

14,488

0.01

757,491,524

73.05

9,991

4

To re-appoint KPMG LLP as auditor of the Company.

752,189,362

99.30

5,269,236

0.70

757,458,598

73.05

42,917

5

To authorise the Directors to fix the remuneration of KPMG LLP as auditor of the Company.

757,426,619

99.99

32,885

0.01

757,459,504

73.05

42,011

6

To elect Ms Anita Kidgell as Director of the Company.

731,948,592

96.65

25,401,836

3.35

757,350,428

73.04

151,087

7

To re-elect Mr David Baynes as a Director of the Company.

756,498,620

99.88

889,906

0.12

757,388,526

73.04

112,989

8

To re-elect Dr Caroline Brown as a Director of the Company.

749,339,961

98.94

8,049,464

1.06

757,389,425

73.04

112,090

9

To re-elect Mr Heejae Chae as Director of the Company.

719,168,838

94.95

38,217,371

5.05

757,386,209

73.04

115,306

10

To re-elect Sir Douglas Flint as a Director of the Company.

741,859,090

97.95

15,525,370

2.05

757,384,460

73.04

117,055

11

To re-elect Ms Aedhmar Hynes as a Director of the Company.

748,385,828

98.81

9,004,528

1.19

757,390,356

73.04

111,159

12

To re-elect Mr Greg Smith as a Director of the Company.

756,781,301

99.92

610,176

0.08

757,391,477

73.04

110,038

13

To re-elect Dr Elaine Sullivan as a Director of the Company.

736,275,915

97.88

15,952,050

2.12

752,227,965

72.54

5,273,550

14

To authorise the Directors to

exercise all the powers of the Company to allot shares and grant rights to subscribe for or to convert any security into shares in the Company subject to the limits set out in the AGM notice.

750,480,664

99.08

6,960,298

0.92

757,440,962

73.05

60,553

15

To empower the Directors to allot equity securities for cash, or sell treasury shares, dis-applying statutory pre-emption rights subject to the limits set out in the AGM notice.

717,892,773

94.78

39,545,240

5.22

757,438,013

73.05

63,502

16

In addition to the authority granted under Resolution 15, to empower the Directors to allot equity securities in connection with an acquisition or other capital investment as if section 561(1) of the Companies Act 2006 ("Act") did not apply to any such allotment, subject to the limits set out in the AGM notice.

697,425,557

92.08

60,011,259

7.92

757,436,816

73.05

64,699

17

To authorise the Company and its subsidiaries to incur political expenditure (as defined in section 365 of the Act) not exceeding £50,000 in total.

721,657,544

95.27

35,833,896

4.73

757,491,440

73.05

10,075

18

To authorise the Company to make market purchases (as defined in section 693(4) of the Act) of the Company's ordinary shares, subject to the limits set out in the AGM notice.

750,533,731

99.11

6,776,371

0.89

757,310,102

73.03

191,413

19

To enable a general meeting other than an Annual General Meeting to be called on not less than 14 clear days' notice.

746,610,050

98.57

10,861,966

1.43

757,472,016

73.05

29,499

 

 

 

In accordance with Listing Rule 9.6.1, a copy of the Resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at:www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism.  

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGLELFFXQLFBBQ
Date   Source Headline
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.